Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 ACCF/AHA Clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association.

× No keyword cloud information.

59 in total

1. Evolving research and stakeholder perspectives on pharmacogenomics.

Authors: Amber L Beitelshees; David L Veenstra
Journal: JAMA Date: 2011-09-21 Impact factor: 56.272

2. Pharmacogenetics and clopidogrel response in patients undergoing percutaneous coronary interventions.

Authors: A L Beitelshees; R B Horenstein; M R Vesely; M R Mehra; A R Shuldiner
Journal: Clin Pharmacol Ther Date: 2011-01-26 Impact factor: 6.875

3. Genetics and cardiovascular disease: a policy statement from the American Heart Association.

Authors: Euan A Ashley; Ray E Hershberger; Colleen Caleshu; Patrick T Ellinor; Joe G N Garcia; David M Herrington; Carolyn Y Ho; Julie A Johnson; Steven J Kittner; Calum A Macrae; Gia Mudd-Martin; Daniel J Rader; Dan M Roden; Derek Scholes; Frank W Sellke; Jeffrey A Towbin; Jennifer Van Eyk; Bradford B Worrall
Journal: Circulation Date: 2012-05-29 Impact factor: 29.690

4. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.

Authors: Jessica L Mega; Tabassome Simon; Jean-Philippe Collet; Jeffrey L Anderson; Elliott M Antman; Kevin Bliden; Christopher P Cannon; Nicolas Danchin; Betti Giusti; Paul Gurbel; Benjamin D Horne; Jean-Sebastian Hulot; Adnan Kastrati; Gilles Montalescot; Franz-Josef Neumann; Lei Shen; Dirk Sibbing; P Gabriel Steg; Dietmar Trenk; Stephen D Wiviott; Marc S Sabatine
Journal: JAMA Date: 2010-10-27 Impact factor: 56.272

Review 5. Pre PCI hospital antithrombotic therapy for ST elevation myocardial infarction: striving for consensus.

Authors: S Michael Gharacholou; Brenda J Larson; Christian C Zuver; Ryan J Wubben; Giorgio Gimelli; Amish N Raval
Journal: J Thromb Thrombolysis Date: 2012-07 Impact factor: 2.300

6. Decreased circulating microRNA-223 level predicts high on-treatment platelet reactivity in patients with troponin-negative non-ST elevation acute coronary syndrome.

Authors: Ying-Ying Zhang; Xin Zhou; Wen-Jie Ji; Rui Shi; Rui-Yi Lu; Jin-Long Li; Guo-Hong Yang; Tao Luo; Jian-Qi Zhang; Ji-Hong Zhao; Tie-Min Jiang; Yu-Ming Li
Journal: J Thromb Thrombolysis Date: 2014-07 Impact factor: 2.300

ACCF/AHA Clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association.

1. Evolving research and stakeholder perspectives on pharmacogenomics.

2. Pharmacogenetics and clopidogrel response in patients undergoing percutaneous coronary interventions.

3. Genetics and cardiovascular disease: a policy statement from the American Heart Association.

4. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.

Review 5. Pre PCI hospital antithrombotic therapy for ST elevation myocardial infarction: striving for consensus.

6. Decreased circulating microRNA-223 level predicts high on-treatment platelet reactivity in patients with troponin-negative non-ST elevation acute coronary syndrome.

7. Identification of CYP2C19*4B: pharmacogenetic implications for drug metabolism including clopidogrel responsiveness.

8. Routine genotyping of patients on clopidogrel: Why the resistance?

9. Does cardiology hold pharmacogenetics to an inconsistent standard? A comparison of evidence among recommendations.

10. Clopidogrel resistance - a clear problem with an unclear solution.